Optimize Your Pipeline’s Therapeutic Index with Novel Delivery Systems to Overcome Endosomal Barriers in Target Cells
Selective cell entry, endosomal barriers and complexities in targeting chemistry have for a long time restricted the ability of promising drug candidates to impactfully target their intracellular sites of action without off-target toxicity implications.
As the ability to manipulate nanomedicine technology goes from strength to strength, the last 12 months have witnessed mounting milestone announcements demonstrating the targeted intracellular delivery of complex payloads is fast becoming a reality. It is now business-critical for biopharma to learn how leveraging the next-generation delivery platforms will unlock the true potential of pipelines, and reveal new opportunities to capitalize on novel drug development.
Built behind a back-bone of biopharma insights, the Targeted Intracellular Delivery Summit will equip Formulation, Chemistry, Delivery and Biology professionals to stay ahead of the curve, as leading biopharma and academic trailblazers unite to address how targeting & vehicular approaches can be deployed to accelerate compounds to the clinic.
As LNPs, Peptide, EV, Polymeric Nanoparticles and Cell-Penetrating Peptides hold promise for the delivery of antisense oligonucleotides, siRNA, mRNA, DNA delivery and peptide protein payloads, here lies your best opportunity to engage with a community prioritizing the safe & effective cytosolic delivery of complex payloads to the liver, lung, oncology indications and beyond!
Your Unmissable Spotlights Included
beyond the liver
& data led
and identify new
nucleic acid &
With significant and common hurdles those targeting intracellular compartments need to address, make sure you’re present for unmissable academic and industry feedback, data & case studies on delivery platform tactics & biological intelligence you can apply to safe-guard your novel pipeline progression in 2023!